Cargando…
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation)
BACKGROUND: The presence of valvular heart disease (VHD) may affect the risk of stroke and mortality in patients with atrial fibrillation (AF). Community‐based estimates of prevalence and outcomes of specific forms of VHD in patients with AF are lacking. METHODS AND RESULTS: We examined the prevalen...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778999/ https://www.ncbi.nlm.nih.gov/pubmed/29273635 http://dx.doi.org/10.1161/JAHA.117.006475 |
_version_ | 1783294454671605760 |
---|---|
author | Thomas, Kevin L. Jackson, Larry R. Shrader, Peter Ansell, Jack Fonarow, Gregg C. Gersh, Bernard Kowey, Peter R. Mahaffey, Kenneth W. Singer, Daniel E. Thomas, Laine Piccini, Jonathan P. Peterson, Eric D. |
author_facet | Thomas, Kevin L. Jackson, Larry R. Shrader, Peter Ansell, Jack Fonarow, Gregg C. Gersh, Bernard Kowey, Peter R. Mahaffey, Kenneth W. Singer, Daniel E. Thomas, Laine Piccini, Jonathan P. Peterson, Eric D. |
author_sort | Thomas, Kevin L. |
collection | PubMed |
description | BACKGROUND: The presence of valvular heart disease (VHD) may affect the risk of stroke and mortality in patients with atrial fibrillation (AF). Community‐based estimates of prevalence and outcomes of specific forms of VHD in patients with AF are lacking. METHODS AND RESULTS: We examined the prevalence of VHD, anticoagulation use, mortality, stroke/transient ischemic attack, and bleeding among a community cohort of patients with AF. Significant VHD was defined as follows: (1) moderate/severe mitral stenosis or mechanical valve; (2) bioprosthetic valve, surgical repair, or balloon valvuloplasty; and (3) moderate/severe aortic regurgitation or stenosis, mitral regurgitation, or tricuspid regurgitation. Proportional hazards models were performed to test the association between VHD groups and outcomes. Among 9748 patients with AF, 2705 (27.7%) had significant VHD. Anticoagulation use was highest among patients with mitral stenosis/mechanical valve (91.8%). Compared with individuals with no significant VHD, individuals with aortic regurgitation/aortic stenosis, mitral regurgitation, or tricuspid regurgitation (hazard ratio, 1.23; 95% confidence interval, 1.07–1.42) had the highest risk of death. There were no differences in stroke or transient ischemic attack and major bleeding among individuals with and without significant VHD. Patients with AF and aortic stenosis had the highest risk of death (hazard ratio, 1.32; 95% confidence interval, 1.08–1.62). CONCLUSIONS: Significant VHD is common among patients with AF in community practice. In a community cohort of patients with AF and CHA (2) DS (2)‐VASc score ≥2, most were anticoagulated. Individuals with AF and moderate‐to‐severe biological VHD have more comorbidities and a higher mortality risk; however, stroke and major bleeding are similar among those with and without significant VHD. |
format | Online Article Text |
id | pubmed-5778999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57789992018-01-26 Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) Thomas, Kevin L. Jackson, Larry R. Shrader, Peter Ansell, Jack Fonarow, Gregg C. Gersh, Bernard Kowey, Peter R. Mahaffey, Kenneth W. Singer, Daniel E. Thomas, Laine Piccini, Jonathan P. Peterson, Eric D. J Am Heart Assoc Original Research BACKGROUND: The presence of valvular heart disease (VHD) may affect the risk of stroke and mortality in patients with atrial fibrillation (AF). Community‐based estimates of prevalence and outcomes of specific forms of VHD in patients with AF are lacking. METHODS AND RESULTS: We examined the prevalence of VHD, anticoagulation use, mortality, stroke/transient ischemic attack, and bleeding among a community cohort of patients with AF. Significant VHD was defined as follows: (1) moderate/severe mitral stenosis or mechanical valve; (2) bioprosthetic valve, surgical repair, or balloon valvuloplasty; and (3) moderate/severe aortic regurgitation or stenosis, mitral regurgitation, or tricuspid regurgitation. Proportional hazards models were performed to test the association between VHD groups and outcomes. Among 9748 patients with AF, 2705 (27.7%) had significant VHD. Anticoagulation use was highest among patients with mitral stenosis/mechanical valve (91.8%). Compared with individuals with no significant VHD, individuals with aortic regurgitation/aortic stenosis, mitral regurgitation, or tricuspid regurgitation (hazard ratio, 1.23; 95% confidence interval, 1.07–1.42) had the highest risk of death. There were no differences in stroke or transient ischemic attack and major bleeding among individuals with and without significant VHD. Patients with AF and aortic stenosis had the highest risk of death (hazard ratio, 1.32; 95% confidence interval, 1.08–1.62). CONCLUSIONS: Significant VHD is common among patients with AF in community practice. In a community cohort of patients with AF and CHA (2) DS (2)‐VASc score ≥2, most were anticoagulated. Individuals with AF and moderate‐to‐severe biological VHD have more comorbidities and a higher mortality risk; however, stroke and major bleeding are similar among those with and without significant VHD. John Wiley and Sons Inc. 2017-12-22 /pmc/articles/PMC5778999/ /pubmed/29273635 http://dx.doi.org/10.1161/JAHA.117.006475 Text en © 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research Thomas, Kevin L. Jackson, Larry R. Shrader, Peter Ansell, Jack Fonarow, Gregg C. Gersh, Bernard Kowey, Peter R. Mahaffey, Kenneth W. Singer, Daniel E. Thomas, Laine Piccini, Jonathan P. Peterson, Eric D. Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) |
title | Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) |
title_full | Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) |
title_fullStr | Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) |
title_full_unstemmed | Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) |
title_short | Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) |
title_sort | prevalence, characteristics, and outcomes of valvular heart disease in patients with atrial fibrillation: insights from the orbit‐af (outcomes registry for better informed treatment for atrial fibrillation) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778999/ https://www.ncbi.nlm.nih.gov/pubmed/29273635 http://dx.doi.org/10.1161/JAHA.117.006475 |
work_keys_str_mv | AT thomaskevinl prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT jacksonlarryr prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT shraderpeter prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT anselljack prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT fonarowgreggc prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT gershbernard prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT koweypeterr prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT mahaffeykennethw prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT singerdaniele prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT thomaslaine prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT piccinijonathanp prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation AT petersonericd prevalencecharacteristicsandoutcomesofvalvularheartdiseaseinpatientswithatrialfibrillationinsightsfromtheorbitafoutcomesregistryforbetterinformedtreatmentforatrialfibrillation |